Circulating cell-free DNA (cfDNA) has been shown to have potential as a non-invasive substrate for the detection and monitoring of tumor cells. As circulating tumor DNA is often present at low frequencies within cfDNA, targeted sequencing is an optimal tool for mutation detection. However, some commercially available cfDNA isolation kits can be difficult to implement.
Advances in next-generation sequencing (NGS) technology has enabled the use of cfDNA as a biomarker for liquid biopsy research applications.
Download this application note to discover:
Technology Networks Limited
Woodview | Bull Lane Industrial Estate | Sudbury | C010 0FD | UK
Email: privacy@technologynetworks.com
© 2019 Technology Networks. All rights reserved
Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy